![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab
In Japan, nivolumab administration is the standard treatment for patients with unresectable advanced or recurrent esophageal squamous cell carcinoma (ESCC) who are refractory or intolerant to fluoropyrimidines...
-
Article
Open AccessClinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
RAS/BRAFV600E mutations are the most remarkable oncogenic driver mutations in colorectal cancer (CRC) and play an important role in treatment selection. No data are available regarding the clinical and prognostic...
-
Article
Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update
Over the last two decades, molecular-targeted agents have become mainstream treatment for many types of malignancies and have improved the overall survival of patients. However, most patients eventually develo...
-
Article
Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab
Nivolumab is a monoclonal antibody directed against programmed death-1 that has been shown to improve survival in patients with metastatic melanoma. However, the efficacy of nivolumab and other agents in melan...
-
Article
Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
Single-agent chemotherapy with third-generation non-platinum agents, such as docetaxel, vinorelbine, is a standard therapeutic option for elderly patients with non-small-cell lung cancer (NSCLC). Subset analys...
-
Article
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. However, there has been no study in wh...
-
Article
Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan
Erlotinib is the first epidermal growth factor receptor–tyrosine kinase inhibitor shown to provide a survival benefit for advanced non-small-cell lung cancer (NSCLC) patients. Adverse drug reactions of erlotin...
-
Article
Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer
The objectives of this phase I trial were to evaluate the toxicity of the nedaplatin/gemcitabine regimen, determine the maximum tolerated doses (MTDs) of these agents, and observe the anti-tumor effects of thi...